

Specialised Immunology Quality Dashboard 2021/22

Indicator Reference Number	Domain	Theme	Measure	Rationale	Name of Indicator/Description	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Interpretation Guidance	Notes	Reporting Periods			
															Q1	Q2	Q3	Q4
PID01	Domain 2: Enhancing quality of life for people with long-term conditions	Clinical process	Immunoglobulin levels measured	This allows adjustment of their dose as and when appropriate	Proportion of patients with immunoglobulin trough levels recorded and documented on the national database	Of those patients in the denominator, the number of patients who have immunoglobulin trough levels recorded and documented on the national database	The total number of long-term immunology patients registered on the national database in the reporting period	Year to date	Quarterly	MDSAS	MDSAS		Higher is better	Immunology only Exclude private patients	Apr 21 - Jun 21	Apr 21 - Sep 21	Apr 21 - Dec 21	Apr 21 - Mar 22
PID03	Domain 2: Enhancing quality of life for people with long-term conditions	Clinical outcome	Homecare offered	Homecare can improve both life expectancy and quality of life for adults with immunodeficiencies	Proportion of long-term immunology patients who are on homecare	Of those patients in the denominator, the number of patients on homecare	The total number of long-term immunology patients registered on the national database in the reporting period	Quarterly	Quarterly	MDSAS	MDSAS		Higher is better	Immunology only Exclude private patients	Apr 21 - Jun 21	Jul 21 - Sep 21	Oct 21 - Dec 21	Jan 22 - Mar 22
PID04	Domain 2: Enhancing quality of life for people with long-term conditions	Workforce	Homecare training	Training patients who are on homecare is part of the draft UKPID standards of care	Proportion of patients on homecare who have received training from an accredited home therapy centre	Of those patients in denominator, the number of patients who received training after accreditation of the home therapy centre	The total number of long-term immunology patients on homecare registered on the national database in the reporting period	Quarterly	Quarterly	MDSAS	MDSAS		Higher is better	Immunology only Exclude private patients	Apr 21 - Jun 21	Jul 21 - Sep 21	Oct 21 - Dec 21	Jan 22 - Mar 22
PID05a	Domain 2: Enhancing quality of life for people with long-term conditions	Clinical process	National database registration	This process supports the appropriate commissioning of IVIG and is part of the national commissioning policy	Proportion of patients with infusions recorded on the national database within 90 days of treatment taking place / product being issued	Of those patients in the denominator, the number with infusions recorded on the national database within 90 days of treatment taking place / product being issued	The total number of long-term immunology patients registered on the national database	Year to date	Quarterly	MDSAS	MDSAS		Higher is better	Immunology only Exclude private patients	Apr 21 - Jun 21	Apr 21 - Sep 21	Apr 21 - Dec 21	Apr 21 - Mar 22
PID15	Domain 2: Enhancing quality of life for people with long-term conditions	Clinical outcome	Annual review	This measures access to immunoglobulin review	Proportion of long-term patients who receive an annual review where a letter is sent to their GP notifying them of the review	Of those patients in the denominator, the number of patients who have an annual review documented on the national database where a letter was sent to their GP notifying them of the review	The total number of long-term immunology patients registered on the national database in the reporting period	Quarterly	Quarterly	MDSAS	MDSAS		Higher is better	GP only relevant for immunology dashboard Exclude private patients	Apr 21 - Jun 21	Jul 21 - Sep 21	Oct 21 - Dec 21	Jan 22 - Mar 22
IVIG05a	Domain 2: Enhancing quality of life for people with long-term conditions	Clinical process	National database registration	This process supports the appropriate commissioning of IVIG and is part of the national commissioning policy	Proportion of patients with infusions recorded on the national database within 90 days of treatment taking place / product being issued	Of those patients in the denominator, the number with infusions recorded on the national database within 90 days of treatment taking place / product being issued	The total number of active patients registered on the national database in the reporting period	Year to date	Quarterly	MDSAS	MDSAS		Higher is better	Exclude private patients	Apr 21 - Jun 21	Apr 21 - Sep 21	Apr 21 - Dec 21	Apr 21 - Mar 22
IVIG06a	Domain 2: Enhancing quality of life for people with long-term conditions	Clinical process	Outcome reporting for grey indication	Provides outcome data for rarely used indications which can inform future national guidelines	Proportion of patients receiving immunoglobulin for grey indications whose outcomes are entered on the national database	Of those in the denominator, the number of patients whose outcomes are entered on the national database	The total number of patients receiving immunoglobulin for grey indications in the reporting period	Year to date	Quarterly	MDSAS	MDSAS		Higher is better	Exclude private patients	Apr 21 - Jun 21	Apr 21 - Sep 21	Apr 21 - Dec 21	Apr 21 - Mar 22
IVIG07	Domain 2: Enhancing quality of life for people with long-term conditions	Clinical process	Dose and dose frequency review	Supports review of dose and reduction in costs of IVIG as dose and/or interval can go up or down	Proportion of long-term patients who have a documented dose review	Of those in the denominator, the number who have a documented dose review	The total number of long-term patients treated in reporting period	Year to date	Quarterly	MDSAS	MDSAS		Higher is better	Exclude private patients	Apr 21 - Jun 21	Apr 21 - Sep 21	Apr 21 - Dec 21	Apr 21 - Mar 22
IVIG08	Domain 2: Enhancing quality of life for people with long-term conditions	Clinical outcome	Recording weight on national database	The weight of all patients treated with immunoglobulin to be recorded on the national immunoglobulin database, as per CQUIN	Proportion of patients treated with immunoglobulin who have their weight documented on the national database	Of those in denominator, the number of patients who have their weight recorded on the national database	The total number of active patients registered on the national database in the reporting period	Year to date	Quarterly	MDSAS	MDSAS		Higher is better	No exclusions	Apr 21 - Jun 21	Apr 21 - Sep 21	Apr 21 - Dec 21	Apr 21 - Mar 22
IVIG10	Domain 2: Enhancing quality of life for people with long-term conditions	Clinical outcome	Registration on national database and retreatment	This will be required as part of the national commissioning policy	Proportion of patients receiving immunoglobulin for short-term conditions who are re-treated within the last 5 years	Of those patients in the denominator, the number who are re-treated for the same condition	The total number of patients receiving immunoglobulin for short-term conditions in the last 5 years	Quarterly	Quarterly	MDSAS	MDSAS		Lower is better	Short-term conditions only Exclude private patients	Apr 21 - Jun 21	Jul 21 - Sep 21	Oct 21 - Dec 21	Jan 22 - Mar 22

Specialised Immunology Quality Dashboard 2021/22

Indicator Reference Number	Domain	Theme	Measure	Rationale	Name of Indicator/Description	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Interpretation Guidance	Notes	Reporting Periods			
															Q1	Q2	Q3	Q4
IVIG11a	Domain 2: Enhancing quality of life for people with long-term conditions	Clinical outcome	Outcome reporting for short-term conditions	Provides outcome data and supports review of the national guidelines.	Proportion of patients receiving immunoglobulin for designated short-term red / blue indication whose outcomes are entered on the national database	Of those patients in the denominator, the number whose outcomes are entered on the national database	The total number of patients receiving immunoglobulin for designated short-term red / blue indications in the reporting period	Year to date	Quarterly	MDSAS	MDSAS		Higher is better	Short-term red / blue indication diagnosis only Exclude private patients	Apr 21 - Jun 21	Apr 21 - Sep 21	Apr 21 - Dec 21	Apr 21 - Mar 22
IVIG12	Domain 2: Enhancing quality of life for people with long-term conditions	Clinical process	MDT panel review for grey and grey unlisted indications	Informs commissioners of appropriate approval of use of immunoglobulin by Trust	Proportion of grey and grey unlisted patients who have been reviewed and approved by a Multi Disciplinary Team (MDT) panel, and who are documented on the national database before commencing immunoglobulin therapy	Of those patients in the denominator, the number who have been reviewed and approved by a MDT panel, and who is documented on the national database before immunoglobulin therapy is commenced	The total number of patients commencing immunoglobulin treatment for grey and grey unlisted indications in the reporting period	Quarterly	Quarterly	MDSAS	MDSAS		Higher is better	Grey and grey unlisted patients only Exclude private patients	Apr 21 - Jun 21	Jul 21 - Sep 21	Oct 21 - Dec 21	Jan 22 - Mar 22
IVIG13	Domain 2: Enhancing quality of life for people with long-term conditions	Clinical outcome	Improvement in neurological condition	Provides outcome data in specific neurological indications	Proportion of long-term neurology patients who have objective measures of improvement documented	Of those patients in the denominator, the number who have objective measures of improvement documented	The total number of long-term Neurology patients treated in the reporting period	Year to date	Quarterly	MDSAS	MDSAS		Higher is better	Neurology patients only Exclude private patients	Apr 21 - Jun 21	Apr 21 - Sep 21	Apr 21 - Dec 21	Apr 21 - Mar 22
IVIG15a	Domain 2: Enhancing quality of life for people with long-term conditions	Clinical outcome	Annual review	Access to immunoglobulin review	Proportion of long-term patients who receive an 'annual review' or an 'on going review'	Of those patients in the denominator, the number who receive an 'annual review' or an 'on going review'	The total number of eligible long-term patients registered with infusions who are recorded on the national database in the reporting period	Year to date	Quarterly	MDSAS	MDSAS		Higher is better	Include only patients who have been treated for at least 365 days Exclude private patients	Apr 21 - Jun 21	Apr 21 - Sep 21	Apr 21 - Dec 21	Apr 21 - Mar 22

Data collection has been approved by the Review of Central Returns - ROCR
ROCR/OR/2230/001MAND